Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 4/2011

01-04-2011 | Letter to the Editor

Successful treatment with very low-dose etanercept in a patient with etanercept-induced liver dysfunction

Authors: Masahiro Iwamoto, Seiji Minota

Published in: Rheumatology International | Issue 4/2011

Login to get access

Excerpt

Etanercept is a fusion protein that composes the soluble TNF receptor p75 and Fc region of immunoglobulin G1. Etanercept is usually administered subcutaneously at a dose of 10 or 25 mg twice a week in Japanese patients with rheumatoid arthritis (RA). There are a few reports of etanercept-induced liver dysfunction [1, 2]. …
Literature
1.
Leak AM, Rincon-Aznar B (2008) Hepatotoxicity associated with etanercept in psoriatic arthritis. J Rheumatol 35:2286–2288PubMedCrossRef
2.
Metadata
Title
Successful treatment with very low-dose etanercept in a patient with etanercept-induced liver dysfunction
Authors
Masahiro Iwamoto
Seiji Minota
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1456-8

Other articles of this Issue 4/2011

Rheumatology International 4/2011 Go to the issue

Case Report

Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy

Original Article

Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis

Review

The role of intra-articular hyaluronan (Sinovial®) in the treatment of osteoarthritis

Original Article

Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis

Case Report

Anaplastic large cell lymphoma in a patient with rheumatoid arthritis

Original Article

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits